Skip to main content
Innovations Inspired by
life
Search
Menu
Search
Hamburger
Our Company
Who we are
History
Culture
Board of Directors
Leadership Team
OUR RESEARCH
Therapeutic focus
Delivery Technologies
Research Programs
R&D Pipeline
Our Medicines
Xelpros®
Elepsia® XR
Business Development
Strategy
Partner with us
Investors
Who we are
Financials
Annual reports
Presentations
Chairman's Speech
Committees of BOD's
Shareholding pattern
Announcements & Disclosures
Policies & Codes
Listing Information
Board of Directors
FAQ’s
Investors Contact
Go green
IEPF
Media
Press Releases
Presentations
Careers
Overview
Apply Now
Contact Us
Media
»
Press Releases
Media
Press Releases
Presentations
Press Releases
22-Sep-2020
SPARC Licenses Commercialization Rights of ElepsiaTM XR to Tripoint Therapeutics
19-Aug-2020
SPARC to Provide Update on R&D Pipeline
28-May-2020
SPARC enters into a worldwide license agreement for SCD-044 with Sun Pharma
13-Feb-2020
SPARC to Provide Update on TaclantisTM NDA
19-Dec-2019
SPARC acquires Bioprojet’s rights for SCD-044
09-Dec-2019
SPARC Provides Update on Paclitaxel Injection Concentrate for Suspension (PICS) Litigation
05-Nov-2019
SPARC Enters into a Licensing Deal with CMS
22-Aug-2019
SPARC to Provide Update on R&D Pipeline
08-Jul-2019
SPARC Receives Orphan Drug Designation from the USFDA for SCO-088 for the Treatment of Patients with Chronic Myeloid Leukemia
01-Jul-2019
SPARC Announces U.S. FDA Acceptance of NDA for TaclantisTM (Paclitaxel Injection Concentrate for Suspension) for Filing and Regulatory Review
Pagination
Current page
1
Page
2
Page
3
Next page
››
Last page
Last »
